Therapy News and Research

RSS

Children with type 1 diabetes benefit from rapid-acting insulin analogues; potential harm remains unclear

Due to a lack of suitable studies, it remains unclear whether children and adolescents with type 1 diabetes benefit more or less from long-term treatment with rapid-acting insulin analogues than with short-acting human insulin.

19 Dec 2009

Subitizing vision therapy for improving math skills

"The incidence of individuals with a mathematics learning disability is between 6-7% of the population." Since there are more than 300 million individuals in the United States, up to 21 million men, women, and children may be affected by this disorder. Sidney Groffman OD, MA, FCOVD, Professor Emeritus at SUNY College of Optometry, author of the article published in the December 2009 issue of Optometry & Vision Development, also says, "This is unfortunate because math skills are of prime importance in everyday life enabling us to understand number concepts and do calculations. Math ability is essential for many occupations and professions."

19 Dec 2009

Applied Technology Holdings opens new 25,000-square-foot facility in California

Applied Technology Holdings, Inc., today announced the opening of its new headquarters in Mission Viejo, California. The new 25,000-square-foot facility will bring employees from its MVP Sports Technologies and Applied Medical Group Subsidiaries together into one Mission Viejo neighborhood, and will enhance the collaboration between ATH's Physical Therapy, Medical, Sports, Product Design, Strategy, and Technology groups.

19 Dec 2009

Only half of eligible heart failure patients receive implantable devices

A study of heart failure patients who meet national guidelines for devices that stabilize and strengthen the heart's electrical system found that only half of eligible patients received the devices.

19 Dec 2009

Annual diabetes Consumer Guide to be published in the January 2010 issue by Diabetes Forecast

When shopping for a new cell phone or even a car, there are dozens of features to explore and choices to make. The same is true of shopping for medical products that will help manage a chronic disease.

19 Dec 2009

SCCA's infection control program leads to suppression of potential H1N1 pandemic

Despite a 100-fold increase in H1N1 influenza cases in the Seattle area during spring 2009, an aggressive infection control program to protect immunocompromised cancer patients and thorough screening measures resulted in no corresponding increase in H1N1 cases among the total patient population at the Seattle Cancer Care Alliance, according to a new study by researchers and physicians at Fred Hutchinson Cancer Research Center and the SCCA.

19 Dec 2009

Recent releases in Global Health

A Scientific American article examines recent efforts to tackle neglected tropical diseases (NTDs). The author writes "NTDs have plagued humankind for thousands of years. … What is new, however, is that donors, drugmakers, health ministries in low- and middle-income countries, the World Health Organization (WHO), and public-private partnerships are linking their efforts to combat the NTDs in a more coordinated and systematic way."

18 Dec 2009

John Theurer Cancer Center presents over 20 research updates and trial results at the 2009 ASH meeting

Doctors and researchers from the John Theurer Cancer Center at Hackensack University Medical Center recently presented research updates and clinical trial results of more than 20 innovative studies at the American Society of Hematology (ASH) annual meeting from December 5-8, 2009.

18 Dec 2009

UVA acquires Extend to broaden the potential for Gamma Knife Perfexion

Patients with overly large benign skull base tumors, lesions too close to critical anatomy and those with multiple brain metastases are among those who will benefit first from a new "frameless" device for use with Leksell Gamma Knife Perfexion systems.

From Elekta 18 Dec 2009

Roundup of health policy research and analyses

Urban Institute/Robert Wood Johnson Foundation: What Would Health Care Reform Mean for Small Employers and Their Workers? - "Small employers and their workers face a broad assortment of barriers to obtaining health insurance coverage today," such as "high administrative costs, limited ability to spread health care risk, and a low-wage workforce."

18 Dec 2009

Tackle Cancer Foundation calls attention to REVLIMID for myeloma patients

The TACKLE CANCER FOUNDATION wants to call attention to important news for patients with the blood cancer multiple myeloma. A new study shows patients benefit from daily medical treatments to keep their cancer in check after they have had a stem cell (bone marrow) transplant. The current standard of care is to give patients the transplant and then hold off on additional treatment until they relapse. The new study shows continuous treatment with the oral drug REVLIMID following the transplant significantly prolongs remission, increasing time to disease progression.

18 Dec 2009

PolyMedix completes first two segments of its PMX-30063 antibiotic drug candidate Phase 1B study

PolyMedix, Inc., an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders, has successfully completed the first two segments of a Phase 1B clinical safety study with its novel antibiotic drug candidate PMX-30063.

18 Dec 2009

Flamel Technologies initiates IFN-alpha-2b XL Phase 2a clinical trial for HCV

Flamel Technologies today announced the initiation of a Phase 2a clinical trial of Flamel’s Interferon alpha-2b XL (IFN-alpha-2b XL), which is based on Flamel’s Medusa® platform for controlled release of biologics. IFN-alpha-2b XL is being developed as a controlled release of unmodified interferon alpha-2b for the treatment of chronic hepatitis C virus (HCV).

18 Dec 2009

European CHMP announces positive opinion for Amgen's Prolia marketing authorization

Amgen Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has announced a positive opinion for the marketing authorization of Prolia((TM)) (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.

18 Dec 2009

AEterna Zentaris terminates its agreement on cetrorelix with sanofi-aventis U.S.

AEterna Zentaris Inc. (the "Company"), a global biopharmaceutical company focused on oncology and endocrine therapy, today announced the termination of its agreement with sanofi-aventis U.S. ( SNY) dated March 5, 2009 for the development, commercialization and licensing of cetrorelix in benign prostatic hyperplasia (BPH) for the U.S. market, following the Company's announcement last week of the results for its European Phase 3 study for cetrorelix in BPH.

18 Dec 2009

Medela announces award recipients from November Virtual Human Milk Collection Campaign

Medela announced today the award recipients from its November Virtual Human Milk (breastmilk) Collection Campaign in honor of the March of Dimes' National Prematurity Awareness Month. More than 4,100 participated in the campaign, voting for their preferred Neonatal Intensive Care Unit.

18 Dec 2009

ANIS2's second edition on ‘micro and nanotechnologies for cancer research’ is open for registrations

There is still time until January 8 2010 to register for the second edition of the Alp NanoBio International School (ANIS2), which will be held in Sterzing/Vipiteno (Bozen, Italy) from 11 to 15 of January 2010, organized by the Centre of Excellence LATEMAR - funded by MIUR, in collaboration with the Fondazione Bruno Kessler (FBK).

18 Dec 2009

New stem cell based technology may eliminate brain cancer

Using a novel stem cell based technology of Cellonis Biotechnologies, Beijing, a Chinese research/medical team may eliminate a glioma -- brain cancer -- of a 36 year old Norwegian patient in a hospital in Beijing.

18 Dec 2009

Alliance HealthCare Services provides financial guidance for full-year 2010

Alliance HealthCare Services, Inc., a leading national provider of outpatient diagnostic imaging and radiation therapy services, reaffirmed 2009 guidance and announced financial guidance for full year 2010.

18 Dec 2009

Physicians favor agents that can reduce HbA1c levels by 2% in diabetes patients

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that over 70 percent of surveyed U.S. physicians indicate there is a high need for diabetes drugs with novel mechanisms of action versus 15 percent who say there is a high need for additional DPP-IV inhibitors.

18 Dec 2009

Therapy News and Research

Children with type 1 diabetes benefit from rapid-acting insulin analogues; potential harm remains unclear

Subitizing vision therapy for improving math skills

Applied Technology Holdings opens new 25,000-square-foot facility in California

Only half of eligible heart failure patients receive implantable devices

Annual diabetes Consumer Guide to be published in the January 2010 issue by Diabetes Forecast

SCCA's infection control program leads to suppression of potential H1N1 pandemic

Recent releases in Global Health

John Theurer Cancer Center presents over 20 research updates and trial results at the 2009 ASH meeting

UVA acquires Extend to broaden the potential for Gamma Knife Perfexion

Roundup of health policy research and analyses

Tackle Cancer Foundation calls attention to REVLIMID for myeloma patients

PolyMedix completes first two segments of its PMX-30063 antibiotic drug candidate Phase 1B study

Flamel Technologies initiates IFN-alpha-2b XL Phase 2a clinical trial for HCV

European CHMP announces positive opinion for Amgen's Prolia marketing authorization

AEterna Zentaris terminates its agreement on cetrorelix with sanofi-aventis U.S.

Medela announces award recipients from November Virtual Human Milk Collection Campaign

ANIS2's second edition on ‘micro and nanotechnologies for cancer research’ is open for registrations

New stem cell based technology may eliminate brain cancer

Alliance HealthCare Services provides financial guidance for full-year 2010

Physicians favor agents that can reduce HbA1c levels by 2% in diabetes patients

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News